Novavax Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Novavax stock.
View analyst ratings for Novavax or view top-rated stocks.

Wall Street analysts have given Novavax a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Novavax wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Novavax saw a increase in short interest in the month of August. As of August 13th, there was short interest totaling 7,180,000 shares, an increase of 21.9% from the July 29th total of 5,890,000 shares. Based on an average daily volume of 4,960,000 shares, the days-to-cover ratio is presently 1.4 days. Currently, 9.8% of the company's stock are sold short.
View Novavax's Short Interest.

Novavax is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Novavax.

Novavax, Inc. (NASDAQ:NVAX) posted its earnings results on Thursday, August, 5th. The biopharmaceutical company reported ($4.75) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($3.63) by $1.12. The biopharmaceutical company earned $298.02 million during the quarter, compared to the consensus estimate of $370.80 million. Novavax had a negative net margin of 80.37% and a negative trailing twelve-month return on equity of 150.88%. During the same period last year, the business posted ($0.30) EPS.
View Novavax's earnings history.

Novavax's stock was trading at $10.51 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NVAX stock has increased by 2,057.1% and is now trading at $226.71.
View which stocks have been most impacted by COVID-19.

Novavax shares reverse split on Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 9th 2019. An investor that had 100 shares of Novavax stock prior to the reverse split would have 5 shares after the split.

6 equities research analysts have issued twelve-month price objectives for Novavax's shares. Their forecasts range from $161.00 to $294.00. On average, they anticipate Novavax's share price to reach $249.60 in the next year. This suggests a possible upside of 10.1% from the stock's current price.
View analysts' price targets for Novavax or view top-rated stocks among Wall Street analysts.

46 employees have rated Novavax CEO Stanley C. Erck on Glassdoor.com. Stanley C. Erck has an approval rating of 71% among Novavax's employees.

Some companies that are related to Novavax include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Repligen (RGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR), Exelixis (EXEL) and Halozyme Therapeutics (HALO).
View all of NVAX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Moderna (MRNA), NVIDIA (NVDA), Tesla (TSLA), Palo Alto Networks (PANW), Advanced Micro Devices (AMD), Egalet (EGLT), Exact Sciences (EXAS) and Pfizer (PFE).

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

Novavax's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.96%), RA Capital Management L.P. (3.44%), State Street Corp (2.27%), Susquehanna International Group LLP (0.00%), Citadel Advisors LLC (0.00%) and Franklin Resources Inc. (1.48%). Company insiders that own Novavax stock include Gary C Evans, Gregory M Glenn, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, Rachel K King and Stanley C Erck.
View institutional ownership trends for Novavax.

NVAX stock was sold by a variety of institutional investors in the last quarter, including UBS Asset Management Americas Inc., RA Capital Management L.P., Price T Rowe Associates Inc. MD, Northern Trust Corp, IMC Chicago LLC, Geode Capital Management LLC, Franklin Resources Inc., and Creative Planning. Company insiders that have sold Novavax company stock in the last year include Gary C Evans, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, and Stanley C Erck.
View insider buying and selling activity for Novavax or view top insider-selling stocks.

NVAX stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Simplex Trading LLC, PEAK6 Investments LLC, State Street Corp, Sumitomo Mitsui Trust Holdings Inc., Legal & General Group Plc, Swiss National Bank, and Ikarian Capital LLC. Company insiders that have bought Novavax stock in the last two years include Gregory M Glenn, James F Young, and Rachel K King.
View insider buying and selling activity for Novavax or or view top insider-buying stocks.

Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVAX stock can currently be purchased for approximately $226.71.

Novavax has a market capitalization of $16.89 billion and generates $475.60 million in revenue each year. The biopharmaceutical company earns $-418,260,000.00 in net income (profit) each year or ($7.27) on an earnings per share basis.

Novavax employs 791 workers across the globe.

Novavax was founded in 1987.

The official website for Novavax is www.novavax.com.

Novavax is headquartered at 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878.

Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company can be reached via phone at (240) 268-2000 or via email at [email protected].